Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11242335
Fluorine-substituted indazole compounds and uses thereof
granted -
US 11241512
Stabilized radio-labeled anti-CD45 immunoglobulin compositions
granted -
US 11241498
Room temperature stable lyophilized protein
granted -
US 11241483
Methods of treating mild brain injury
granted -
US 11241473
Bicyclic peptide ligands and uses thereof
granted -
US 11241460
Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
granted -
US 11241451
Modulators of IRF4 expression
granted -
US 11241478
Adenovirus-associated viral vectors for expressing variants of tetratricopeptide repeat (TPR)-containing Rab8b interacting (TRIP8b) protein in neurons and uses thereof for treating major depressive disorder (MDD)
granted -
US 11241445
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 11241499
Human serum albumin in formulations
granted -
US 11241380
Porous photonic crystals for drug delivery to the eye
granted -
US 11241415
N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor
granted -
US 11241406
Compositions and methods for acutley raising nitric oxide levels
granted -
US 11241394
Treating vasculature related diseases or disorders using nanoparticles
granted -
US 11241458
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
granted -
US 11242543
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 11242339
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted -
WO 2022029639
FORMULATIONS PHARMACEUTIQUES AMÉLIORÉES COMPRENANT DES INHIBITEURS DE PI3K
granted -
US 11248270
Methods and kits to identify Klebsiella strains
granted -
US 11246947
Recombinant AAV-crumbs homologue composition and methods for treating LCA-8 and progressive RP
granted -
US 11246940
Peptides whose uptake in cells is controllable
granted -
US 11248039
Immunoglobulin single variable domain antibody against RSV prefusion F protein
granted -
US 11248056
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 11246859
Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers
granted -
US 11248044
Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor
granted -
US 11246926
Polynucleotides encoding anti-C1s antibodies
granted -
US 11248213
Platform for generating safe cell therapeutics
granted -
US 11248022
Glypican-3 peptide reagents and methods
granted -
US 11247969
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 11247971
Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
granted -
US 11247968
Lipocationic dendrimers and uses thereof
granted -
US 11246961
Engineered scaffolds for vascularized tissue repair
granted -
US 11246930
Reoviruses having modified sequences
granted -
US 11246937
One-step processing of hydrogels for mechanically robust and chemically desired features
granted -
US 11246881
Nanoparticle to target cancer
granted -
US 11246875
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 11247985
Phenyl indole allosteric inhibitors of P97 ATPase
granted -
US 11246871
Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
granted -
US 11246858
Immunoresponsive methods of treating tumors
granted -
US 11247974
Small molecules that enable cartilage rejuvenation
granted -
US 11246933
Biodegradable lipids for the delivery of active agents
granted -
US 11246950
Combination cancer immunotherapy with pentaaza macrocyclic ring complex
granted -
US 11254940
Inhibition of MAP4K4 through RNAi
granted -
US 11254640
N-substituted indoles and other heterocycles for treating brain disorders
granted -
US 11254913
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 11254662
2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
granted -
US 11255865
Immunoassay for human erythroferrone
granted -
US 11253506
Compounds, compositions and methods for preventing and/or treating chlorine inhalation toxicity and/or injury
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.